197 related articles for article (PubMed ID: 29373500)
1. Evaluation of Two-Diabetes Related microRNAs Suitability as Earlier Blood Biomarkers for Detecting Prediabetes and type 2 Diabetes Mellitus.
Al-Muhtaresh HA; Al-Kafaji G
J Clin Med; 2018 Jan; 7(2):. PubMed ID: 29373500
[TBL] [Abstract][Full Text] [Related]
2. Differential expression of microRNAs in plasma of patients with prediabetes and newly diagnosed type 2 diabetes.
Yan S; Wang T; Huang S; Di Y; Huang Y; Liu X; Luo Z; Han W; An B
Acta Diabetol; 2016 Oct; 53(5):693-702. PubMed ID: 27039347
[TBL] [Abstract][Full Text] [Related]
3. Altered levels of circulating cytokines and microRNAs in lean and obese individuals with prediabetes and type 2 diabetes.
Nunez Lopez YO; Garufi G; Seyhan AA
Mol Biosyst; 2016 Dec; 13(1):106-121. PubMed ID: 27869909
[TBL] [Abstract][Full Text] [Related]
4. Can miR-145-5p be used as a marker in diabetic patients?
Shahrokhi SZ; Saeidi L; Sadatamini M; Jafarzadeh M; Rahimipour A; Kazerouni F
Arch Physiol Biochem; 2022 Oct; 128(5):1175-1180. PubMed ID: 32412315
[TBL] [Abstract][Full Text] [Related]
5. Dysregulated miR-103 and miR-143 expression in peripheral blood mononuclear cells from induced prediabetes and type 2 diabetes rats.
Vatandoost N; Amini M; Iraj B; Momenzadeh S; Salehi R
Gene; 2015 Nov; 572(1):95-100. PubMed ID: 26164754
[TBL] [Abstract][Full Text] [Related]
6. Blood-based analysis of 84 microRNAs identifies molecules deregulated in individuals with type-2 diabetes, risk factors for the disease or metabolic syndrome.
Avgeris M; Kokkinopoulou I; Maratou E; Mitrou P; Boutati E; Scorilas A; Fragoulis EG; Christodoulou MI
Diabetes Res Clin Pract; 2020 Jun; 164():108187. PubMed ID: 32360711
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs-1299, -126-3p and -30e-3p as Potential Diagnostic Biomarkers for Prediabetes.
Weale CJ; Matshazi DM; Davids SFG; Raghubeer S; Erasmus RT; Kengne AP; Davison GM; Matsha TE
Diagnostics (Basel); 2021 May; 11(6):. PubMed ID: 34073154
[TBL] [Abstract][Full Text] [Related]
8. Circulating miR-148b-3p and miR-27a-3p can be potential biomarkers for diagnosis of pre-diabetes and type 2 diabetes: integrating experimental and in-silico approaches.
Ghoreishi E; Shahrokhi SZ; Kazerouni F; Rahimipour A
BMC Endocr Disord; 2022 Aug; 22(1):207. PubMed ID: 35978298
[TBL] [Abstract][Full Text] [Related]
9. Decreased expression of microRNAs targeting type-2 diabetes susceptibility genes in peripheral blood of patients and predisposed individuals.
Kokkinopoulou I; Maratou E; Mitrou P; Boutati E; Sideris DC; Fragoulis EG; Christodoulou MI
Endocrine; 2019 Nov; 66(2):226-239. PubMed ID: 31559537
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of miR-1 and miR-133 in pre-diabetes.
Al-Kafaji G; Al-Muhtaresh HA; Salem AH
Biomed Rep; 2021 Mar; 14(3):33. PubMed ID: 33585035
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes.
Al-Kafaji G; Al-Mahroos G; Alsayed NA; Hasan ZA; Nawaz S; Bakhiet M
Mol Med Rep; 2015 Nov; 12(5):7485-90. PubMed ID: 26460159
[TBL] [Abstract][Full Text] [Related]
12. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study.
Seyhan AA; Nunez Lopez YO; Xie H; Yi F; Mathews C; Pasarica M; Pratley RE
Sci Rep; 2016 Aug; 6():31479. PubMed ID: 27558530
[TBL] [Abstract][Full Text] [Related]
13. Circulating endothelium-enriched microRNA-126 as a potential biomarker for coronary artery disease in type 2 diabetes mellitus patients.
Al-Kafaji G; Al-Mahroos G; Abdulla Al-Muhtaresh H; Sabry MA; Abdul Razzak R; Salem AH
Biomarkers; 2017; 22(3-4):268-278. PubMed ID: 27321479
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of Circulating Cardiomyocyte-Enriched miR-1 and miR-133 Associate with the Risk of Coronary Artery Disease in Type 2 Diabetes Patients and Serve as Potential Biomarkers.
Al-Muhtaresh HA; Salem AH; Al-Kafaji G
J Cardiovasc Transl Res; 2019 Aug; 12(4):347-357. PubMed ID: 30610670
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker.
Al-Kafaji G; Al-Mahroos G; Al-Muhtaresh HA; Skrypnyk C; Sabry MA; Ramadan AR
Exp Ther Med; 2016 Aug; 12(2):815-822. PubMed ID: 27446281
[TBL] [Abstract][Full Text] [Related]
16. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study.
Kong L; Zhu J; Han W; Jiang X; Xu M; Zhao Y; Dong Q; Pang Z; Guan Q; Gao L; Zhao J; Zhao L
Acta Diabetol; 2011 Mar; 48(1):61-9. PubMed ID: 20857148
[TBL] [Abstract][Full Text] [Related]
17. Serum miRNA Signatures Are Indicative of Skeletal Fractures in Postmenopausal Women With and Without Type 2 Diabetes and Influence Osteogenic and Adipogenic Differentiation of Adipose Tissue-Derived Mesenchymal Stem Cells In Vitro.
Heilmeier U; Hackl M; Skalicky S; Weilner S; Schroeder F; Vierlinger K; Patsch JM; Baum T; Oberbauer E; Lobach I; Burghardt AJ; Schwartz AV; Grillari J; Link TM
J Bone Miner Res; 2016 Dec; 31(12):2173-2192. PubMed ID: 27345526
[TBL] [Abstract][Full Text] [Related]
18. A plasma circulating miRNAs profile predicts type 2 diabetes mellitus and prediabetes: from the CORDIOPREV study.
Jiménez-Lucena R; Camargo A; Alcalá-Diaz JF; Romero-Baldonado C; Luque RM; van Ommen B; Delgado-Lista J; Ordovás JM; Pérez-Martínez P; Rangel-Zúñiga OA; López-Miranda J
Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30598522
[TBL] [Abstract][Full Text] [Related]
19. miR-10b and miR-223-3p in serum microvesicles signal progression from prediabetes to type 2 diabetes.
Parrizas M; Mundet X; Castaño C; Canivell S; Cos X; Brugnara L; Giráldez-García C; Regidor E; Mata-Cases M; Franch-Nadal J; Novials A
J Endocrinol Invest; 2020 Apr; 43(4):451-459. PubMed ID: 31721085
[TBL] [Abstract][Full Text] [Related]
20. Circulating miR-146a, miR-34a and miR-375 in type 2 diabetes patients, pre-diabetic and normal-glycaemic individuals in relation to β-cell function, insulin resistance and metabolic parameters.
García-Jacobo RE; Uresti-Rivera EE; Portales-Pérez DP; González-Amaro R; Lara-Ramírez EE; Enciso-Moreno JA; García-Hernández MH
Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1092-1100. PubMed ID: 31355469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
